These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 12661270)

  • 1. Landmark study demonstrates survival benefit at 10 years for breast cancer patients.
    Oncology (Williston Park); 2003 Mar; 17(3):387. PubMed ID: 12661270
    [No Abstract]   [Full Text] [Related]  

  • 2. Epirubicin regimen cuts risk of death in premenopausal women with early breast cancer.
    Oncology (Williston Park); 1999 Dec; 13(12):1740. PubMed ID: 10631703
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
    Nisticò C; De Matteis A; Rossi E; Carnino F; Valenza R; Agostara B; Bria E; Farris A; Cremonesi M; D'Ottavio AM; Vaccaro A; Garufi C; Giunta S; Botti C; Perrone F; Terzoli E
    Anticancer Res; 2005; 25(2B):1343-8. PubMed ID: 15865089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
    Alliot C
    J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
    [No Abstract]   [Full Text] [Related]  

  • 7. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
    Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
    Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L
    Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
    Gupta S
    Nat Clin Pract Oncol; 2005 Feb; 2(2):80-1. PubMed ID: 16264879
    [No Abstract]   [Full Text] [Related]  

  • 13. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
    Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-arterial chemotherapy: a safe treatment for elderly patients with locally advanced breast cancer.
    Pacetti P; Mambrini A; Paolucci R; Sanguinetti F; Palmieri B; Della Seta R; Muttini MP; Fiorentini G; Cantore M
    In Vivo; 2006; 20(6A):761-4. PubMed ID: 17203763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin/vinorelbine adjuvant chemotherapy in young women with breast cancer is associated with preservation of menstrual function.
    Zekri JM; El-Helw LM; Purohit OP; Hatton MQ; Coleman RE
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):513-6. PubMed ID: 18513930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
    J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
    Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T
    J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
    Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
    Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
    Bonneterre J; Roché H; Kerbrat P; Brémond A; Fumoleau P; Namer M; Goudier MJ; Schraub S; Fargeot P; Chapelle-Marcillac I
    J Clin Oncol; 2005 Apr; 23(12):2686-93. PubMed ID: 15837983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.